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Abstract
There is increasing evidence for beneficial effects of early DMARD
(disease-modifying antirheumatic drug) therapy over delayed
treatment in patients who present with arthritis of recent onset.
However, no universal consensus exists concerning the choice of
initial drug or whether single drugs or combinations should be
given as initial treatments. Recent studies have focused on the
benefits of various strategies in which treatments were tailored to
achieve low levels of disease activity, as assessed using validated
response criteria. These studies demonstrated superiority of
‘aggressive’ over ‘conventional’ approaches. Whether the inclusion
of tumour necrosis factor antagonists or other biologic targeted
therapies in such strategies confers additional benefits in terms of
improved long-term outcomes must be clarified by further studies.
Assessment of risks in the individual patient, allowing individual
‘tailoring’ of the initial treatment, would be desirable.
Introduction
Diagnostic and treatment paradigms for rheumatoid arthritis
(RA) and other potentially destructive arthritides have
changed over recent years. Based on recognition of the risks
that these diseases convey for patients in terms of quality of
life and mortality [1-4], it has become a ‘mantra’ to diagnose
and treat as early as possible [5]. Parallel to this development
it has been recognized that conventional criteria for
classification of destructive arthritides such as RA or psoriatic
arthritis are not applicable to the early stages of these
diseases [6,7]. However, many practicing physicians, in
particular when they are less familiar with the multifaceted
clinical appearances of these diseases, may be reluctant to
begin administering potentially harmful drugs before a
threshold of diagnostic certainty (such as the ‘four criteria
fulfilment’ of the classification criteria for RA [8]) has been
reached. On the other hand it has been recognized that
delaying treatment, especially in high(er) risk patients, or
inadequate treatment that does not control disease activity
sufficiently may be quite detrimental in the long run [9].
Which strategies of treatment for early (rheumatoid) arthritis
are optimal in which patients remains a subject of debate.
Some evidence can be derived from studies published during
recent years. This review focuses on the results of such
studies and their possible implications for future therapeutic
directions. It must be borne in mind, however, that most of
these studies included patients with ‘rheumatoid arthritis’ in
its early stages; the term ‘early arthritis’, on the other hand,
encompasses a broader spectrum of diseases, which may
differ from RA both in prognosis and response to therapy and
in long-term outcomes.
Are there advantages of early DMARD
treatment?
The hallmark of RA is the destructive inflammatory process,
which – by virtue of the (bone and cartilage) damage induced
in afflicted joints – leads to functional impairment and disability.
The destruction is essentially irreversible, and repeated
periods of active inflammation in a particular joint add further
damage to pre-existing destruction. It is therefore clear that
preventing, retarding, or halting damage early may have
significant long-term benefits. Disease-modifying anti-
rheumatic drugs (DMARDs) are the mainstay of RA therapy
because of their significant effect on inflammation, damage
and function. Their benefit in terms of preservation of joint
structure as well as preventing disability in RA (mostly of long
disease duration) is well established. Meta-analyses and
retrospective analyses of large patient cohorts have revealed
that responses to DMARDs or their retention rates are better
in the early stages of the disease [10,11]. Two studies
conducted in the mid-1990s suggested benefit from
instituting DMARDs earlier than after the then customary
waiting period of up to several years [12,13]. Egsmose and
coworkers [12] conducted a double-blind, placebo-controlled
trial in patients with RA of under 2 years duration; patients
were treated with auranofin or treatment was delayed,
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employing placebo for 8 months instead. Clinical and radio-
logical benefit was seen for the DMARD-treated group at 2
and 5 years. Van der Heide and coworkers [13] randomized
238 consecutive patients with early RA to receive DMARDs
(hydroxychloroquine, intramuscular gold, or oral methotrexate;
7.5–15 mg/week) either immediately or with a delay, in an
open-label manner. Both functional and clinical outcomes
significantly favoured early DMARD treatment, and the control
group had almost four times more treatment discontinuations.
The observations of these studies have since been confirmed
by numerous others, in which treatment with DMARDs was
started earlier than 2 years after onset [14-19] or even earlier
than 3 months [20]. Whether some DMARDs are more
efficacious than others in such early (or very early) disease
remains a matter of debate.
These studies suggest benefit from early therapy compared
with a delayed start of DMARD therapy, at least during the
initial year(s) of RA. Longer term extensions of these studies
demonstrate that after the initial ‘head start’ conferred by
early (aggressive) therapy, the rates of clinical success in the
‘conventional’ and ‘aggressive’ treatment groups converge
[21-23]. Analysis of radiological progression rates, however,
revealed a preserved advantage (despite identical clinical
outcome) in the aggressively (and early) treated patients
[21,22]. In the Utrecht cohort [23], in which ‘aggressive’
treatment was not mandated by the protocol and in which
‘time to DMARD’ was the principal difference between the
two groups, the radiological damage scores in both groups
approached each other and appeared to be identical during
later stages. Thus, it remains to be determined whether the
benefit observed after 1 or 2 years of early treatment may
remain clinically relevant after 1 or 2 decades.
The complexities of the problem are highlighted by a report
on 5-year outcomes in the Norfolk Arthritis Register [24]. In
this inception cohort, patients with early inflammatory
polyarthritis (not RA) were included and followed regularly
over an extended period [25]. This initiative is remarkable in
that it included patients with any kind of arthritis who were
then assessed by a trained research team and followed as
completely and comprehensively as possible over the
following years. The 5-year radiological outcomes of 335
patients indicated that patients who were DMARD treated
had worse radiological outcomes than patients who were
never treated with DMARDs or in whom DMARD start was
delayed for over 12 months. However, the patients without
DMARD treatment or with delayed treatment had milder
disease at baseline, as indicated by several parameters such
as age at onset, delay to presentation, sex, maximal early
morning stiffness, rheumatoid factor titre, Health Assessment
Questionnaire (HAQ), C-reactive protein, and number of
swollen and tender joints. After adjustment for these severity
indicators, early initiation (before 6 months of disease)
resulted in the most favourable outcome in severe RA,
whereas in ‘mild’ cases treatment delay did not adversely
affect radiological progression. Early (versus later) treatment
also appeared to be beneficial in patients who were erosion
free at the time of the first film (which was taken up to 1 year
after onset of disease) in terms of influencing radiographic
outcome at 5 years.
How aggressive should initial therapy be?
In a remarkable reversal of therapeutic paradigms, the
cautious approach employed until the late 20th century,
known as the ‘therapeutic pyramid’ [26], has been reversed
to call for an early, optimally effective initial (DMARD)
treatment. Given the possible toxicity of such an aggressive
approach, as soon as ‘remission’ or a ‘low disease activity
stage’ is reached the dosage should be reduced to the
lowest level required to maintain this disease state.
Several investigations have addressed the issue of whether
initial aggressive treatment of early RA confers benefits over
more conservative strategies. The COBRA trial [15]
compared initial therapy with methotrexate (7.5 mg/week),
sulfasalazine (2 g/day) and prednisolone (starting with
60 mg/day and tapering over 6 months) versus sulfasalazine
monotherapy (without steroids) over 1 year in patients with
RA of duration under 2 years. The FIN-RACo trial [27]
employed sulfasalazine, methotrexate, hydroxychloroquine
and prednisolone in combination (maximum doses: 2 g/day,
15 mg/week, 300 mg/day and 10 mg/day, respectively) in
patients with RA of duration under 2 years for 2 years. The
‘single DMARD group’ patients were sequentially treated with
sulfasalazine, followed by methotrexate and then azathioprine
(or, if deemed necessary, auranofin, hydroxychloroquine,
injectable gold, penicillamine, or podophyllotoxin) if clinical
response was insufficient. This single treatment group also
permitted use of up to 10 mg/day prednisolone. In another
Dutch study, van Jaarsveld and coworkers [28] compared
hydroxychloroquine (if necessary replaced by auranofin) with
intramuscular gold (if necessary replaced by D-penicillamine)
and methotrexate (if necessary replaced by sulfasalazine)
over 2 years in patients with disease duration under 1 year.
Therapy with sulfasalazine, methotrexate and hydroxychloro-
quine as single DMARDs was compared with methotrexate
plus sulfasalazine or methotrexate plus hydroxychloroquine
and triple therapy by Calgüneri and coworkers [29] over
2 years. Proudman and coworkers [30] administered sulfa-
salazine (supplemented with intra-articular or intramuscular
steroids if clinically indicated during the observation period of
1 year) and compared this strategy with a combination of
methotrexate and cyclosporine A in patients with RA of
duration under 1 year. The combination group received initial
intra-articular steroids and subsequently received intra-
articular or intramuscular steroid injections if joints were
clinically active. Two studies [31,32] compared methotrexate,
sulfasalazine and the two agents combined in RA patients of
duration under 1 year and at high risk for aggressive disease
(rheumatoid factor and/or shared epitope positivity) over
1 year.Page 3 of 6
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Benefit of the more aggressive approach over the
‘conservative’ treatment was demonstrated in the COBRA
[15] and FIN-RACo [27] studies as well as in the studies
conducted by van Jaarsveld [28], Calgüneri [29] and
Proudman [30] and their groups. However, the studies
comparing the sulfasalazine/methotrexate combination versus
the single agents [31,32] were unable to identify better
outcomes for any treatment arm over the others, although
there was a nonsignificant trend in favour of combination
therapy.
Important points to be considered in interpreting the findings
of these studies relate to the choice of the DMARDs used in
the ‘aggressive’ or combination arms as well as to the use of
steroids. Thus, although van Jaarsveld and coworkers [28]
employed DMARDs early in all three arms, hydroxy-
chloroquine (regarded to be the least potent of the three
drugs [33]) and intramuscular gold (which has a significant
delay until onset of its effect [34]) were demonstrated to be
inferior to methotrexate with its (relatively) quick onset of
action and greater potency. Both the COBRA study [15] and
the FIN-RACo trial [27] mandated steroid use from the start
in the aggressive arms, and although in the latter study the
permitted steroid dose was identical and the amount of
steroid use was higher in the single DMARD group, steroids
were introduced rather late in this group, at up to 93 weeks
from baseline [35]. The study conducted by Proudman and
coworkers [30] employed both a potent DMARD (metho-
trexate) and a steroid in all patients in the ‘aggressive’ arm,
whereas in the comparator group only 66% of patients
received steroids at all, with a cumulative dose of about one-
third that in the aggressive treatment group. In contrast, the
two trials employing sulfasalazine and methotrexate com-
pared two DMARDs with similar characteristics in terms of
time to onset of treatment effects as well as efficacy in
established RA [36,37]. Thus, a difference in efficacy
between the two agents would have been more difficult to
detect. Moreover, recent data have indicated that the
combination of sulfasalazine and methotrexate should yield
little benefit because of their biologic interactions [38].
Importantly, in all trials using aggressive approaches to initial
treatment of arthritis, all patients – including those treated
with intensive DMARD (and steroid) regimens – deteriorated
with respect to radiological score. No significant differences,
in terms of either number of patients with radiographic
progression or damage scores, were reported by van
Jaarsveld [28], Maillefert [39], Calgüneri [29] and Proudman
[30] and their groups. Arrest of progression in terms of joint
and bone destruction was achieved in only about half of
these early RA patients. Only the COBRA [15] and the Fin-
RACo trials [27] reported radiographic benefits in the high
intensity treatment groups, although the results of the
COBRA trial, in particular, make it very much likely that this
difference was attributable mainly to the early and intensive
use of steroids rather than the combination of DMARDs.
Taken together, a benefit not only of early but also of
aggressive treatment in patients presenting with arthritis of
short duration, at least for the clinical course, seems
achievable, particularly when highly active DMARDs
(sulfasalazine or methotrexate) are combined with (sufficient
doses of) steroids. However, unequivocal benefit of
combination therapy with (‘conventional’) DMARDs is yet to
be demonstrated. Furthermore, even using these intensive
treatment regimens, only a fraction of patients achieved the
‘ideal’ goal, namely halted progression and elimination of
clinical activity (‘remission’). Moreover, in terms of radiological
outcome, progression was observed in a substantial number
of patients despite use of these strategies.
Is therapeutic success a question of
treatment strategy?
A recently published study examined the influence of a strategy
of ‘tight control in RA’ (TICORA) [40]. A total of 110 patients
with RA of duration under 5 years who had not received
combination therapy were randomly assigned to ‘tight’ or
‘routine’ control. A Disease Activity Score (DAS)44 [41] of 2.4
or less was defined as the aim in the TICORA group, and this
was examined monthly. Therapy was escalated according to a
predefined strategy: sulfasalazine 500 mg/day increased to
40 mg/kg/day; progressing to combined sulfasalazine, metho-
trexate 7.5 mg/week and hydroxychloroquine 200-400 mg/day;
progressing to triple therapy with methotrexate up to
25 mg/week; progressing to triple therapy with sulfasalazine up
to 5 g/day followed by addition of prednisolone 7.5 mg/day;
progressing to cyclosporin A at 2-5 mg/kg per day plus
methotrexate 25 mg/week; followed by a change to alternative
DMARD (leflunomide or sodium aurothiomalate) if the DAS44
score was above 2.4. These therapies were given in addition to
intra-articular steroid injections. In the ‘routine’ group patients
were seen every 3 months without formal assessment or
feedback on disease activity scores; therapy adaptation was
thus performed based on the clinical judgement of the
rheumatologist. The TICORA group had significantly more
remissions and European League against Rheumatism
(EULAR) responses as well as American College of Rheuma-
tology (ACR)70 responses. Indicators of quality of life (HAQ,
12-item Short Form) and X-ray progression were also in favour
of the TICORA strategy (although there still was median [inter-
quartile range] progression by 4.5 [1-9.875] points in the Sharp-
van der Heijde score [42] in the TICORA group; in the routine
group this progression was 8.5 [2-15.5]). Remarkably, this
intensive monitoring strategy resulted in a higher treatment reten-
tion rate, a lower rate of discontinuations due to side effects, and
lower costs per patient (based on lower admission costs) than
the routine control over the 18 months of observation.
Can biologics add efficacy in early
rheumatoid arthritis?
In several clinical trials highly potent biologics, such as
tumour necrosis factor (TNF) antagonists, have effectively
improved clinical activity and slowed radiological deterioration
Available online http://arthritis-research.com/content/8/3/211in established disease [43,44]. All three commercially
available TNF antagonists have been tested in methotrexate-
naïve RA patients, although the disease would not
necessarily be regarded as ‘early’ because patients were
included up to 3 years after disease onset [45-47]. These
three trials yielded remarkably similar results: the TNF
antagonists and methotrexate exhibited comparable clinical
efficacy, with similar response rates as estimated by ACR or
EULAR criteria. The combination of etanercept, infliximab and
adalimumab with methotrexate was more effective than
monotherapy. In addition, at least for infliximab, it has been
demonstrated that, even in cases in which clinical activity was
not optimally suppressed (‘poor response’), radiographic
progression appeared to be significantly retarded in
comparison with methotrexate [48].
These results raise expectations that addition of biologics to
the treatment regimen in early RA might be superior to the
results obtained with DMARD combinations or DMARDs
(single or in combination) with steroids. In addition, the
results of the TICORA strategy [40] (adaptation of treatment
according to response, with clearly defined aims to reach
thresholds for low disease activity or remission) indicate
superiority of the intensive control/intensive DMARD/steroid
strategy, with good tolerability.
A recently published study combined these approaches [49].
In an open four arm design, patients with early RA (duration
under 2 years) were assigned to receive one of four treatment
strategies. Similar to the TICORA strategy, the aim was to
reduce the DAS44 score to values below 2.4. A total of 508
patients were allocated to receive one of four strategies. The
first arm (group 1) was the ‘sequential monotherapy’ arm:
methotrexate up to 25-30 mg/week; progressing to sulfa-
salazine; progressing to leflunomide; progressing to metho-
trexate plus infliximab; progressing to gold plus methyl-
prednisolone; and finally progressing to methotrexate plus
cyclosporin A and prednisone. The second arm (group 2), the
‘step-up combination therapy’ arm, involved the following:
methotrexate increased to 25-30 mg/week; progressing to
addition of sulfasalazine, hydroxychloroquine and prednisone,
always added to the current combination; progressing to a
switch to methotrexate plus infliximab; progressing to a
switch to methotrexate with cyclosporine A and prednisone;
progressing to a switch to leflunomide. The ‘step-down
therapy’ arm (group 3) was initially adapted from the COBRA
scheme [15]; the following protocol was followed in case of
insufficient response: increase of methotrexate to
25-30 mg/week; progressing to addition of cyclosporine A
and prednisone; progressing to switch to methotrexate plus
infliximab; progressing to switch to leflunomide monotherapy;
progressing to switch to gold plus methylprednisolone; and
progressing to switch to azathioprine plus prednisone. In the
final arm (group 4) patients were admininstered initial
infliximab plus methotrexate (with increased infliximab dose in
the case of insufficient response).
Treatment was stepped up if the DAS44 score was above
2.4 at any visit; if the DAS44 score was below 2.4 for two
consecutive (three monthly) visits, treatment was reduced to
the ‘previous step’. The end-points in this study were
functional capacity according to HAQ and radiological
progression. A total of 491 patients (97%) completed the
first year, and the aim of a DAS44 score below 2.4 was
reached by significantly more patients in groups 3 and 4 than
in group 1 (71% and 74% versus 53%; P = 0.004). More-
over, retention of initial treatment was significantly more
frequent in groups 3 and 4 due to good response. The HAQ
was significantly more improved in groups 3 and 4 compared
with group 1 after 12 months. In addition, the pace of HAQ
improvement was more rapid in these groups (improvement
by over 60% after 3 months) than in groups 1 and 2 (only
modest improvement after 3 months; marked improvement
only after 9-12 months, but still less than in the two ‘intensive’
groups). In terms of radiological outcomes, the results were
similar: patients in groups 3 and 4 had significantly better
radiological outcomes at 12 months than did those receiving
the two less intense treatment strategies.
Of interest is the observation that 50% of patients in the
infliximab group could stop the biologic at the end of year 1
because of persistent low disease activity. In group 1
(sequential monotherapy), 20% needed methotrexate plus
infliximab. In groups 2 and 3 fewer than 10% were treated
with methotrexate plus infliximab. This trend continued in the
second year of the study, with 26%, 10%, 11% and 19% of
patients on infliximab in groups 1-4 (unpublished personal
communication).
Conclusion
DMARD treatment is clearly beneficial in early arthritis
patients, among whom many will develop destructive arthritis
classifiable as RA. Delaying treatment is justified (if at all) only
in those who present with very mild disease less than
3 months from disease onset. Arthritis that is persistent for
more than 12 weeks is unlikely to remit spontaneously [50];
many of these patients will progress to develop RA and
patients with significant initial disease activity benefit from an
early start of DMARD, even if ‘conventional treatment’ is used.
The ‘best’ initial treatment seems to be less a matter of drug
choice and more a question of whether treatment aims
(‘remission’ or ‘low disease activity’ as defined by available
scores [41,51-55]) are strictly followed. The initial addition of
Arthritis Research & Therapy    Vol 8 No 3 Machold et al.
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encouraged [35,56]. The biologics, in particular TNF
antagonists, appear to confer additional benefits. In early
arthritis patients with high disease activity and/or risk factors
for adverse outcomes (e.g. [high titre] rheumatoid factor or
anti-cyclic citrullinated peptide antibodies [9]), a ‘preventively
aggressive’ strategy including the entire drug armamentarium
available seems justified.
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